Form 8-K - Current report:
SEC Accession No. 0001517022-24-000065
Filing Date
2024-08-08
Accepted
2024-08-08 07:06:18
Documents
15
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K akba-20240808.htm   iXBRL 8-K 31748
2 EX-99 q22024pr.htm EX-99 95405
  Complete submission text file 0001517022-24-000065.txt   281000

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20240808.xsd EX-101.SCH 2258
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20240808_def.xml EX-101.DEF 3738
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20240808_lab.xml EX-101.LAB 25083
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20240808_pre.xml EX-101.PRE 14595
17 EXTRACTED XBRL INSTANCE DOCUMENT akba-20240808_htm.xml XML 2718
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 241185980
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)